Background: Men and women are differently affected by coronary artery disease, suggesting an important role of sex steroids. Moreover, testosterone (T) treatment is increasingly used in elderly males. Therefore, we examined effects of chronic anabolic T administration on left ventricular (LV) remodeling after myocardial infarction (MI). Methods: Adult male rats were treated with intramuscular placebo, testosterone undecanoate (T), or were orchiectomized. After 2 weeks, animals underwent sham-operation (sham) or left coronary artery ligation. Left ventricular remodeling and function was assessed by serial magnetic resonance imaging (MRI) at weeks 2 and 8 and hemodynamic investigation at week 8. Results: In sham operated animals T administration increased serum T levels and led to cardiac hypertrophy, but not to an upregulation of ANP mRNA. The a / b-MHC ratio was significantly higher after T treatment due to an increase in a-MHC. As a potential mechanism for this ''physiologic'' form of hypertrophy, IGF-1 mRNA expression was significantly increased in T treated animals. After coronary artery ligation, infarct size and mortality were similar among the groups. Left ventricular hypertrophy was enhanced by T treatment. However, in vivo LV end-diastolic pressure and wall stress were decreased by T, whereas other hemodynamic parameters (mean arterial pressure, cardiac output, etc.) remained unchanged. Conclusion: Chronic anabolic T treatment led to a specific ''physiologic'' pattern of myocardial hypertrophy with a significant increase in LV weight, but without differences in ANP and with an upregulation in a / b-MHC, possibly mediated by IGF-1. Testosterone treatment had no detrimental effects following MI. Reduced wall stress and LVEDP may even improve long-term outcome.
dose (e.g., ''stacking''). AASs are a heterogeneous group association of androgenic-anabolic steroid (AAS) use and of substances with a variety of actions depending on their detrimental cardiovascular effects both in animals and in metabolic fate (e.g., aromatization, 5a-reduction) [2] and power athletes (for review, see Ref. [1] ). However, studies their interaction with non-androgen receptors and other in humans are mostly case reports or lack adequate control targets [3] . Due to their clandestine use, their clinical groups [1] . They often do not account for important pharmacology is not well understood. In contrast, male gender appears to be associated with a more favorable outcome following myocardial infarction. the hospital after acute MI, during hospitalization higher 2 .2. Experimental MI rates of death have been found in women younger than 75 years of age compared to men of the same age [4] . Two weeks after ORX or non-ORX, MI or sham Moreover, 2-year mortality after MI was also reported to operations were performed in each group. Thus, together, be higher in women than in men [5] . Gender differences in six experimental groups were studied: (1) non-ORX sham long-term mortality after MI may be related to gender operated (non-ORX1sham, n58); (2) non-ORX infarcted differences in cardiac remodeling [6] and differences in (non-ORX1MI, n59); (3) ORX sham operated (ORX1 circulating sex steroids may be of major importance for sham, n515); (4) ORX infarcted (ORX1MI, n59); (5) these findings. Thus one might speculate that higher non-ORX, T treated sham operated (non-ORX1T1sham, endogenous androgen levels contribute to a more favorable n515); and (6) non-ORX, T treated infarcted rats (nonlong-term prognosis after MI in men. Indeed, there is ORX1T1MI, n59) (Fig. 1) . Left coronary artery ligation evidence that natural androgens have a neutral or even was induced by a previously described technique [9] . favorable effect on cardiovascular disease. For example, in Sham operation was performed using an identical prothe Rancho Bernardo study baseline testosterone (T) was cedure, except that the suture was passed under the not associated with subsequent cardiovascular mortality in coronary artery without ligation. Mortality rate of infarcted elderly men [7] . Even more, there is some evidence for an rats within first 24 h after the operation was 40 to 50%. association of low T and cardiovascular disease in men [8] reducing conditions (Laemmli Sample buffer, Bio-Rad ) operation, hemodynamic measurements were performed as with 5% b-mercaptoethanol; 6% separation gel with 5% described previously [11] . Left ventricular systolic and glycerol; 8.7 V/ cm for 18 h). The gels were silver stained end-diastolic pressures (LVSP, LVEDP), mean arterial (Silver Stain Plus kit, Bio-Rad), scanned, and analyzed pressure (MAP) and heart rate (HR) were measured under using ScanPacK 3.0 software. light ether anesthesia and spontaneous respiration.
.10. Statistical analysis .5. Immunoassays
All data were expressed as mean6standard error of the After 10 weeks, serum T was measured by a commermean (S.E.M.). Calculations were performed as previously cially available RIA (Diagnostic Products Corporation, described [14] . For multiple comparisons analysis of USA) with a sensitivity of 0.06 ng / ml. The intra-and variance (ANOVA) was used, followed by Scheffe's inter-assay variabilities ranged between 6-15% and 9-corrections. Statistical significance was achieved if two-16%, respectively. 17b-estradiol was also measured by a tailed P values were less than 0.05. Mortality was calcucommercially available RIA (Diagnostic Products Corpolated by Chi-square statistics. ration) with a lower detection limit of 3.5 pg / ml.
. Results

.6. Northern blot of atrial natriuretic peptide (ANP)
and IGF 3 .1. Baseline characteristics RNA was isolated and Northern blots were performed as As intended, T serum levels were supraphysiological previously described [12] . The ANP probe was a gift of C.
after T treatment and below the lower limit of detection Seidman (Boston, MA, USA), the IGF probe was a gift of after ORX (T vs. placebo, 12.961.7 vs. 2.960.9 ng / ml, L. Tsao (Boston, MA, USA). P,0.001). In sham operated and T treated animals no major side effects were observed although T treated 2 .7. Western blot animals seemed to be more aggressive. T treatment for 10 weeks significantly reduced body weight, an effect similar For Western blots, tissue was lysed in RIPA buffer.
to the weight loss seen in estrogen treated female rats. Membranes were incubated with a phospho-Akt (Ser473, However, skeletal muscle and LV mass increased sigCell Signaling, Beverly, MA, USA) antibody overnight, nificantly as measured by MRI (see Figs. 2 and 3 and followed by washing and incubation with a matching Table 1 ). The hormonal status had no influence on LV secondary antibody and autoradiographed. The same memfunction and in vivo hemodynamic data (ejection fraction, branes were stripped and incubated with an Akt antibody cardiac output, MAP, LVEDP) (see Table 2 ). (Cell Signaling) accordingly.
LV hypertrophy is usually associated with an increase of ANP and a down regulation of the a / b-MHC ratio through 2 .8. Quantitative assessment of myocardial collagen an upregulation of b-MHC. However, LV hypertrophy due to T treatment was not accompanied by an increase in Quantitative myocardial collagen assessment was per-ANP mRNA expression and b-MHC, but by an upregulaformed with picrosirius red staining and polarized light as tion of the a / b-MHC ratio. This was due to a dose described by Whittaker et al. [13] . Shortly, serial 3 mm dependent increase in a-MHC by T (Fig. 4) . Furthermore, sections of the interventricular septum from six rat hearts / T treatment induced IGF-1 mRNA expression about group were taken. Sections were examined on a Leitz fivefold in the myocardium when compared to placebo (Laborlux S) microscope (Leitz, Wetzlar, Germany) using treated animals (see Fig. 5A ). Also Akt, a downstream either brightfield or polarized light. Images were analyzed target of IGF, was activated about twofold as demonstrated using ScionImage Release 4b (Scion Corporation, USA).
by its phosphorylation at Ser473 (see Fig. 5B ). Collagen fractional area remained unchanged (non-ORX1sham vs. different among groups (see Table 1 ). in younger men with chronic disease over the last years [15] , but also in the use of testosterone T in elderly males mass (week 8 post MI, MI1ORX vs. non-ORX1MI vs.
with an age-related decline in endogenous T secretion non-ORX1T1MI, 825633 vs. 882644 vs. 965653 mg, (''male menopause'') [16] . However, it is still an unsettled P,0.05) and skeletal mass (week 8 post MI, MI1ORX vs. matter, whether this decline represents a true hormonal non-ORX1MI vs. non-ORX1T1MI, 14564 vs. 16865 deficiency or a physiological adaptation. T supple-3 vs. 18865 mm , P,0.05) increased significantly. Eight mentation is, therefore, rather a pharmacological interven- MI size5Assessed by MRI; HW5heart weight (measured by scale), BW5body weight 10 weeks after treatment randomization; DLV mass5assessed by MRI (difference week 10 and 2); DEDV5increase in end-diastolic volume assessed by MRI (difference week 10 and 2), T5testosterone serum levels, 17b-E2517b-estradiol. tion than the substitution of a true deficit. Safety issues of and clearly differs from the effects seen after mechanical androgen administration are thus of growing importance.
overload. This concerns in particular cardiovascular effects of T, as
Although not tested in our study, these effects are most coronary heart disease is highly prevalent in elderly males.
likely the result of direct steroid hormone action on cardiac Therefore, we have analyzed the effects of T under myocytes. Androgen receptors in the heart have been baseline conditions and in the clinically most relevant described for several species including rats and humans experimental heart failure model, the rat coronary artery [17] and are known to mediate hypertrophy in cardiac ligation model. myocytes [18] . However, despite a clear hypertrophic enhances the expression of a-MHC mRNA [19] . This However, T treatment favored the expression of a-MHC regulation was independent of hemodynamic load or and not of b-MHC as usually expected under conditions of cardiac hypertrophy in stroke-prone spontaneous hypertenpathological cardiac hypertrophy. Thus T-induced hypersive rats [20] . Thus, the observed changes in myosin heavy trophy is associated with a more ''physiologic'' phenotype chain expression (MHC) are most likely the consequence of direct androgen effects on cardiac myocytes. Moreover, as in our study, androgen-induced cardiac hypertrophy using nandrolone decanoate did not change cardiac collagen content [21] . Administration of this androgenic steroid in high doses-alone or in combination with exercise-was not associated with alterations in either the quantity or the quality of left ventricular collagen. However, it was associated with an increase of end diastolic stiffness, an effect that we did not observe. As discussed below, these differences might be due to the dose regimens used or due to the different metabolism of testosterone, e.g., estradiol generation due to aromatase activity. What could the mechanism for this kind of hypertrophy without pathological hypertrophy markers or collagen accumulation be? Although not formally tested, the explanation may be related to the dose-dependent T-induced increase in IGF-1 mRNA expression and the activation of its downstream targets like Akt. IGF-1 but not growth hormone is known to activate a hypertrophic response in neonatal myocardial cells [22] . Moreover, IGF-1 mRNA levels and protein content are increased after induction of hypertension in the rat suggesting that IGF-1 may be involved in mediating left ventricular hypertrophy. Further, over, cardiac specific overexpression of IGF can rescue LVEDP was significantly reduced in T treated animals tropomodulin overexpressing transgenic mice from the together with wall stress without differences in diastolic development of a dilated myopathy and premature death filling rates following MI. [24] . Of note, IGF-1 treatment caused no induction of These findings may seem to be somehow contradictory cardiac collagen synthesis in rats further supporting the to the notion that the use of AASs is associated with concept of a role of local IGF-1 in androgen-induced significant cardiac toxicity in athletes and in experimental hypertrophy. To our knowledge induction of cardiac IGF-1 animals. In vitro direct cardiac toxicity has been described expression and of its downstream targets by T has not been for a variety of AAS using ventricular myocytes [27] . described before. However, it has been shown that anToxicity varied widely between different agents. T esters drogens are necessary for the local production of IGF-1 were especially more toxic than T itself (e.g., T enanthate within skeletal muscle, as induction of hypogonadism in and T cypionate) [28] . However, since, in practice, T esters normal young men results in a reduction in IGF-1 mRNA act as depot preparations from which T is gradually levels in skeletal muscle [25] . In addition, treatment of released, these findings have little bearing on the clinical hypogonadal elderly men led to an increase in IGF-1 pharmacology of androgens. Moreover, toxic effects obmRNA levels in muscle biopsy specimens [26] . Thus, served in vitro required steroid concentrations several skeletal muscle and cardiac muscle may respond in a orders of magnitude above those used in our study or for similar fashion to T by increasing local IGF-1 production.
treatment of chronic disease in humans.
The cardiovascular risk of AAS in humans is difficult to 4 .2. Testosterone and myocardial infarction assess due to their clandestine use. It is largely based on case reports [1] . High doses of a variety of substances are We found no evidence for cardiac toxicity of T adminisoften used as part of ''stacking'' protocols with unpredicttration despite a 10-fold increase in T levels after testoable toxicity. In contrast, no adverse cardiovascular effects sterone undecanoate administration compared to placebo were observed in randomized trials using supraphysiologiadministration. Neither infarct size nor procedure-related cal T doses [29] . Furthermore, in support of our findings, mortality was influenced by T status. In contrast, there was van Kesteren et al. [30] investigated mortality and mora tendency to an improved hemodynamic outcome: bidity in transsexual subjects treated with cross-sex hor-
